Table 2 Description of Patient Clinical Characteristics at the Visit Date
Characteristic | All Patients N = 414 | SU* + MF† n = 341 | TZD** + MF† n = 73 |
|---|---|---|---|
A1c at on the follow-up period (mean ± std) | 7.3 ± 1.2 | 7.4 ± 1.3 | 7.0 ± 1.2 |
Patients at A1C Goal (%) | 24.88% | 23.75% | 30.14% |
Therapy patients were using at the time of visit (also referred as "current therapy") – (%) | |||
Monotherapy (%) | 3.16% | 3.24% | 2.78% |
Combination Therapy | |||
Metformin + Sulfonylurea (%) | 57.52% | 69.12% | 2.78% |
Metformin + TZDs (%) | 16.26% | 3.24% | 77.78% |
Sulfonylurea + TZD (%) | 0.24% | 0.29% | 0.00% |
Sulfonylurea + Alpha glucosidase inhibitors (%) | 0.73% | 0.88% | 0.00% |
Sulfonylureas + TZD + Metformin (%) | 11.89% | 12.65% | 8.33% |
Sulfonylureas + Alpha glucosidase inhibitors + Metformin (%) | 5.83% | 7.06% | 0.00% |
Metformin + TZD + Alpha glucosidase inhibitors (%) | 1.46% | 0.59% | 5.56% |
Sulfonylureas + TZD + Metformin + Alpha glucosidase inhibitors (%) | 2.91% | 2.94% | 2.78% |